Six-Month Overall Survival Benefit with RenovoGem Versus Systemic Chemotherapy, and 65% reduction in adverse effects and clinically meaningful overall survival trend
Results highlight RenovoGem’s potential to change treatment paradigm for Locally Advanced Pancreatic Cancer
https://finance.yahoo.com/news/renovorx-announces-positive-interim-phase-120000387.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.